When does Stelara's SPC expire in Europe?
Stelara's Supplementary Protection Certificate (SPC) is set to expire in Europe on October 18, 2027 [1]. This expiration date applies to the European Union and the United Kingdom [1].
What does SPC expiry mean for Stelara?
The expiry of Stelara's SPC will remove the market exclusivity currently held by its originator, Janssen [2]. This paves the way for generic versions of Stelara, known as biosimilars, to enter the European market [2]. Biosimilar versions are highly similar to the original biologic drug and are expected to offer more affordable treatment options for patients [3].
What are the implications of Stelara's SPC expiry for biosimilar competition?
Following the SPC expiry, multiple biosimilar manufacturers are anticipated to launch their versions of Stelara in Europe [2]. Companies like Alvotech, Fresenius Kabi, and Celltrion have already developed biosimilar candidates for ustekinumab, the active ingredient in Stelara [2]. The availability of these biosimilars is expected to increase competition, potentially leading to lower prices and greater access to ustekinumab treatment across European countries [3].
What is Stelara used for?
Stelara (ustekinumab) is a medication used to treat several inflammatory conditions, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis [4]. It works by targeting specific proteins (interleukins) involved in the inflammatory process [4].
How will biosimilar entry affect the cost of Stelara treatment in Europe?
The introduction of biosimilar ustekinumab is projected to significantly reduce the cost of treatment for Stelara [3]. This price reduction is a key benefit of biosimilar competition, making these advanced biologic therapies more accessible to a wider patient population and easing the financial burden on healthcare systems [3].
What is the regulatory pathway for biosimilars in Europe?
In Europe, biosimilars undergo a rigorous scientific and regulatory review process by the European Medicines Agency (EMA) to demonstrate their high degree of similarity to the reference biologic drug [3]. This process ensures that biosimilars are safe and effective for patient use [3].
Are there any ongoing legal challenges impacting Stelara's patent or SPC status?
While the primary SPC expiry date is October 18, 2027, the landscape of drug patent and exclusivity can be complex. Companies often challenge patents and SPCs to gain earlier market entry for their generic or biosimilar products. Information on specific legal challenges pertaining to Stelara's European exclusivity can be found on specialized patent tracking resources like DrugPatentWatch.com [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.biosimilarinfo.org/
[3] https://www.ema.europa.eu/en/human-regulatory/overview/biosimilars
[4] https://www.janssen.com/